Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vanda Pharmaceuticals Inc.VNDA · Entity 5861 | Director | June 04, 2026 | June 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vanda Pharmaceuticals Inc.
Report date June 04, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 219,054 |
Reported balance
After 2026-06-04 transaction · row 1
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 41,600 · Balance 219,054 F1: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 4, 2027, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 4, 2027, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2026 Filed Jun 8, 2026 20:20 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 41,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-261800 · ownership.xml · nonDerivative · entry 1 DUGAN RICHARD W · CIK 0001263499 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 219,054 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 4, 2027, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 21:35 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 59,225 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-083888 · ownership.xml · nonDerivative · entry 1 DUGAN RICHARD W · CIK 0001263499 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 177,454 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 5, 2026, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| May 17, 2024 Filed May 21, 2024 20:53 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantStock Option (Right to Buy) · Derivative | 37,578 | $0.00 Strike: $5.48 | $0.00 |
DisclosureSEC source: 0000950170-24-063019 · ownership.xml · derivative · entry 2 DUGAN RICHARD W · CIK 0001263499 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,578 Underlying: Common Stock · 37,578 shares Expires 2034-05-16 F2 · derivative.exercise_date: This option vests and becomes exercisable with respect to 100% of the option shares on May 17, 2025, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| May 17, 2024 Filed May 21, 2024 20:53 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 20,529 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-063019 · ownership.xml · nonDerivative · entry 1 DUGAN RICHARD W · CIK 0001263499 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,229 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 17, 2025, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 20:18 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantStock Option (Right to Buy) · Derivative | 33,960 | $0.00 Strike: $6.50 | $0.00 |
DisclosureSEC source: 0001209191-23-036280 · doc4.xml · derivative · entry 2 DUGAN RICHARD W · CIK 0001263499 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,960 Underlying: Common Stock · 33,960 shares Expires 2033-06-07 F2 · derivative.exercise_date: This option vests and becomes exercisable with respect to 100% of the option shares on June 8, 2024, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 20:18 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 17,307 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-036280 · doc4.xml · nonDerivative · entry 1 DUGAN RICHARD W · CIK 0001263499 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,700 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 8, 2024, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 20:54 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantStock Option (Right to Buy) · Derivative | 24,707 | $0.00 Strike: $9.37 | $0.00 |
DisclosureSEC source: 0001209191-22-038447 · doc4.xml · derivative · entry 2 DUGAN RICHARD W · CIK 0001263499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,707 Underlying: Common Stock · 24,707 shares Expires 2032-06-15 F2 · derivative.exercise_date: This option vests and becomes exercisable with respect to 100% of the option shares on June 16, 2023, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 20:54 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 12,006 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-038447 · doc4.xml · nonDerivative · entry 1 DUGAN RICHARD W · CIK 0001263499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,393 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 16, 2023, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| May 31, 2022 Filed Jun 2, 2022 20:47 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $4.15 | $0.00 |
DisclosureSEC source: 0001209191-22-033561 · doc4.xml · derivative · entry 3 DUGAN RICHARD W · CIK 0001263499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2022-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested in 12 equal monthly installments beginning on July 14, 2012. Read SEC document |
| May 31, 2022 Filed Jun 2, 2022 20:47 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 6,500 | $9.85 | $64,052.30 |
DisclosureSEC source: 0001209191-22-033561 · doc4.xml · nonDerivative · entry 2 DUGAN RICHARD W · CIK 0001263499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,387 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy the exercise price of the stock options, which were scheduled to expire June 13, 2022 as reflected in this Form 4. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.75 to $9.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| May 31, 2022 Filed Jun 2, 2022 20:47 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionCommon Stock | 15,000 | $4.15 | $62,250.00 |
DisclosureSEC source: 0001209191-22-033561 · doc4.xml · nonDerivative · entry 1 DUGAN RICHARD W · CIK 0001263499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,887 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 20:35 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $19.21 | $0.00 |
DisclosureSEC source: 0001209191-21-040237 · doc4.xml · derivative · entry 2 DUGAN RICHARD W · CIK 0001263499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-06-09 F2 · derivative.exercise_date: This option vests and becomes exercisable with respect to 100% of the option shares on June 10, 2022, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 20:35 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-040237 · doc4.xml · nonDerivative · entry 1 DUGAN RICHARD W · CIK 0001263499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,887 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 10, 2022, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 01:43 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $7.11 | $0.00 |
DisclosureSEC source: 0001209191-21-012204 · doc4.xml · derivative · entry 3 DUGAN RICHARD W · CIK 0001263499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2021-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested in 12 equal monthly installments beginning on July 16, 2011. Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 01:43 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 5,754 | $18.54 | $106,663.05 |
DisclosureSEC source: 0001209191-21-012204 · doc4.xml · nonDerivative · entry 2 DUGAN RICHARD W · CIK 0001263499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,887 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy the exercise price of the stock options, which were scheduled to expire June 15, 2021 as reflected in this Form 4. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.25 to $18.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 01:43 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionCommon Stock | 15,000 | $7.11 | $106,650.00 |
DisclosureSEC source: 0001209191-21-012204 · doc4.xml · nonDerivative · entry 1 DUGAN RICHARD W · CIK 0001263499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,641 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 23:11 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $10.57 | $0.00 |
DisclosureSEC source: 0001209191-20-036782 · doc4.xml · derivative · entry 2 DUGAN RICHARD W · CIK 0001263499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-06-10 F2 · derivative.exercise_date: This option vests and becomes exercisable with respect to 100% of the option shares on June 11, 2021, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 23:11 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-036782 · doc4.xml · nonDerivative · entry 1 DUGAN RICHARD W · CIK 0001263499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,641 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 11, 2021, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| May 28, 2020 Filed May 29, 2020 20:10 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionNonstatutory Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $7.38 | $0.00 |
DisclosureSEC source: 0001209191-20-032896 · doc4.xml · derivative · entry 3 DUGAN RICHARD W · CIK 0001263499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2020-06-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested in 12 equal monthly installments beginning on July 3, 2010. Read SEC document |
| May 28, 2020 Filed May 29, 2020 20:10 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 10,129 | $11.04 | $111,805.93 |
DisclosureSEC source: 0001209191-20-032896 · doc4.xml · nonDerivative · entry 2 DUGAN RICHARD W · CIK 0001263499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,641 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy the exercise price and certain tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the exercise of certain stock options, which were scheduled to expire June 2, 2020 as reflected in this Form 4. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.99 to $11.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| May 28, 2020 Filed May 29, 2020 20:10 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionCommon Stock | 15,000 | $7.38 | $110,700.00 |
DisclosureSEC source: 0001209191-20-032896 · doc4.xml · nonDerivative · entry 1 DUGAN RICHARD W · CIK 0001263499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,770 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 26, 2019 Filed Aug 28, 2019 20:30 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionNonstatutory Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $14.78 | $0.00 |
DisclosureSEC source: 0001209191-19-047610 · doc4.xml · derivative · entry 3 DUGAN RICHARD W · CIK 0001263499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2019-08-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested in 12 equal monthly installments beginning on September 27, 2009. Read SEC document |
| August 26, 2019 Filed Aug 28, 2019 20:30 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 15,000 | $14.85 | $222,750.00 |
DisclosureSEC source: 0001209191-19-047610 · doc4.xml · nonDerivative · entry 2 DUGAN RICHARD W · CIK 0001263499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,770 F1 · kind: Represents shares of common stock sold to cover the payment of the option exercise price (which represents 99.94% of the proceeds from the sales made by the Reporting Person) of the option, which was set to expire on August 26, 2019. Read SEC document |
| August 26, 2019 Filed Aug 28, 2019 20:30 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionCommon Stock | 15,000 | $14.78 | $221,700.00 |
DisclosureSEC source: 0001209191-19-047610 · doc4.xml · nonDerivative · entry 1 DUGAN RICHARD W · CIK 0001263499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,770 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 21:03 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $15.04 | $0.00 |
DisclosureSEC source: 0001209191-19-037411 · doc4.xml · derivative · entry 2 DUGAN RICHARD W · CIK 0001263499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-06-12 F2 · derivative.exercise_date: This option vests and becomes exercisable with respect to 100% of the option shares on June 13, 2020, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 21:03 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-037411 · doc4.xml · nonDerivative · entry 1 DUGAN RICHARD W · CIK 0001263499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,770 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 13, 2020, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 20:31 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $18.30 | $0.00 |
DisclosureSEC source: 0000899243-18-016771 · doc4.xml · derivative · entry 2 DUGAN RICHARD W · CIK 0001263499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-06-12 F2 · derivative.exercise_date: This option vests and becomes exercisable with respect to 100% of the option shares on June 13, 2019, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 20:31 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-016771 · doc4.xml · nonDerivative · entry 1 DUGAN RICHARD W · CIK 0001263499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,770 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 13, 2019, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| March 19, 2018 Filed Mar 20, 2018 21:02 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $4.98 | $0.00 |
DisclosureSEC source: 0001209191-18-020921 · doc4.xml · derivative · entry 2 DUGAN RICHARD W · CIK 0001263499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2018-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options vested in 12 equal monthly installments beginning on June 8, 2008. Read SEC document |
| March 19, 2018 Filed Mar 20, 2018 21:02 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionCommon Stock | 15,000 | $4.98 | $74,700.00 |
DisclosureSEC source: 0001209191-18-020921 · doc4.xml · nonDerivative · entry 1 DUGAN RICHARD W · CIK 0001263499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,770 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2017 Filed Jun 19, 2017 21:08 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $13.75 | $0.00 |
DisclosureSEC source: 0001209191-17-040881 · doc4.xml · derivative · entry 2 DUGAN RICHARD W · CIK 0001263499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-06-14 F2 · derivative.exercise_date: This option vests and becomes exercisable with respect to 100% of the option shares on June 15, 2018, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| June 15, 2017 Filed Jun 19, 2017 21:08 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-040881 · doc4.xml · nonDerivative · entry 1 DUGAN RICHARD W · CIK 0001263499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,770 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 15, 2018, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.